Alerte De Sécurité sur ARCHITECT ESTRADIOL REAGENT

Selon National Institute of Drugs and Food Surveillance (INVIMA), ce/cet/cette alerte de sécurité concerne un dispositif en/au/aux/à Colombia qui a été fabriqué par Importer: ABBOTT LABORATORIES DE COLOMBIA S.A.

Qu'est-ce que c'est?

Les alertes fournissent des informations importantes et des recommandations concernant les dispositifs médicaux. Le fait qu'une alerte soit émise ne signifie pas nécessairement qu'un dispositif soit dangereux. Les alertes de sécurité, qui sont envoyées tant aux travailleurs du secteur médical qu'aux utilisateurs de ces dispositifs, peuvent inclure des rappels. Elles peuvent être rédigées par des fabricants mais aussi par des autorités en charge de la santé.

En savoir plus sur les données ici
  • Type d'événement
    Safety alert
  • ID de l'événement
    IRD-010416
  • Numéro de l'événement
    INVIMA 2006RD-0000038
  • Date
    2016-04-06
  • Pays de l'événement
  • Source de l'événement
    INVIMA
  • URL de la source de l'événement
  • Notes / Alertes
    Colombian data is current through June 2019. All of the data comes from the National Institute of Drugs and Food Surveillance (INVIMA), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Colombia.
  • Notes supplémentaires dans les données
  • Cause
    Abbott has confirmed that the drug fulvestrant (faslodex®) can interfere with the architect estradiol trial (reference number: 7k72), which can lead to falsely elevated estradiol results.

Device

  • Modèle / numéro de série
    Reference: 7K72, all lots
  • Description du dispositif
    IMMUNOANALYSIS CHIMIOLUMINISCENT OF MICROPARTICLES (CMIA) FOR THE QUALITATIVE DETERMINATION OF HORMONES IN HUMAN DEORIGEN SAMPLES
  • Manufacturer

Manufacturer

  • Société-mère du fabricant (2017)
  • Commentaire du fabricant
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source
    NIDFSINVIMA